We translate a chemical into what it actually does — then find every industry in the world that needs that.

PROWL — Pattern Recognition Of White-space Leads — does not search your molecule's name. It works out what the substance does. Then it reads the hardest technical and commercial evidence there is, looking for anywhere that behaviour is already wanted. Each candidate is then tested: is it real, is it worth it, can we win. A person makes every judgement.

A chemical's name tells you almost nothing about where it can sell.

This is the step that is usually missing, and it is the one that decides everything after it. Searching a trade name or a CAS number returns the markets you already serve, because those are the people who already use that word. The markets you do not serve do not call it what you call it. So the first job is to stop working in names and start working in function.

Identity

What the substance actually is, resolved against the registers: the identifiers, the chemical family, the forms it is genuinely sold in — and which of those forms have quietly ceased.

Function

What it does. Interfacial behaviour, thermal and oxidative stability, biological activity, compatibility. Properties as measured and published, never as claimed. This is the language industries actually buy in.

Industrial use, worldwide

Who needs that function, in any industry and any region — not one sector, and not one continent. The same behaviour is called different things in adhesives, in agriculture, in energy and in personal care, and each of those names has to be recognised as the same thing.

Market, in your words

Uses are grouped into markets through your own ontology, so what comes back is expressed the way your business describes itself — and what you already serve is subtracted before anything is ranked.

Why translate a chemical into function rather than search its name?
Because the industry that needs your molecule is not the one that already buys it — and it does not use your name for it. Searching the name finds the markets you already serve. Searching the function finds the ones you do not.
Across 8 kinds of public source, read in full. Each use becomes a record carrying the sentence, the document and a live link, and every search is kept, so the list can be audited rather than believed.

Most of the evidence is hard to read on purpose.

This is not a matter of volume alone. The documents that decide the question are written in four different professional registers, none of them written for a commercial reader, and each has to be understood on its own terms before anything can be compared across them.

Legal and regulatory

Registration dossiers, consent orders, restriction notices, food-contact inventories. Written by lawyers for regulators. Precise, deliberately narrow, and full of consequences that are never stated as conclusions — a declared use, a ceased identity and a missing entry each mean something quite different.

Patents

Drafted to claim as broadly as possible while disclosing as little as the law allows. Your chemistry usually appears as somebody else's input, unnamed, described by function or by family. Filings show intent rather than revenue, and are read that way.

Academic literature

Written for specialists in a field that is probably not yours, with the commercially decisive result sitting in a methods section or a supplementary table rather than the abstract.

Trade and market data

Customs and volume data carry numbers without narrative; research houses carry narrative without a register behind it. Each is recorded for what it is — verified in a register, or asserted by someone selling a report — and the two are never blended into one confident sentence.

Why does the difficulty of the material matter commercially?
Because the evidence that changes a decision is rarely in the document that looks promising. It is a clause in a dossier, a dependent claim in a patent, or a line in a supplementary table. Material like that is not skimmable, which is exactly why it goes unread — and why it is still there to be found.
8 kinds of public source, read in full rather than sampled. Every fact carries its source and the date it was read.

The point is the range. Every industry, not one. The sector that needs your molecule is not the sector you sell to now. It is probably not on your continent. And nobody in your building reads its journals.

Qualify — is it real, is it worth it, can we win?

Three questions, answered from named public sources — open sources before paid.

Is it real? Does it exist at scale?

And do independent sources agree that it does?

Is it worth it? As-is, or with work?

Does it sell as the molecule stands, or does it need formulation work first? Those are two different sales.

Can we win? The route in.

Who buys, who is there already, the route in, and the demand driver behind it.

A ranked list is not a plan.

What comes out of Qualify is not a score. It is the beginning of a commercial strategy for expansion into that market.

The sale, named

Does it sell as the molecule stands, or does it need formulation work first? Those are two different sales, to two different buyers, on two different timescales.

The route in

Direct to the formulator, or through specialty distribution. Who is incumbent, what they hold, and where the window is — measured in filings per year rather than in sentiment.

What is blocked, and why

Blocked markets are reported too, with what opening them would take. A closed door with a named lock is more useful than an open door that isn't there.

Who signs off on a conclusion?
A person, always. The AI drafts each conclusion and a person reviews and approves it before it goes anywhere. Blocked markets are reported too, with what opening them would take.
Every fact carries its source and date. The machine drafts; a person signs.

A market you looked at once is a market you looked at once.

Evidence goes stale. A lead that was real in March can be taken, priced out or regulated away by September, and nothing about the original report will tell you. So PROWL keeps reading — on a cadence, against the same sources, reporting only what actually moved.

Live leads every 30 days

Leads still in play are read again every month; everything else every quarter. A market you already sell into is never read again — news cannot overturn the fact that you are already there.

Movement, not rewording

Each reading is compared against the last on the evidence itself — the quoted source text, not our summary of it. A fact described in different words is not a change, and is not reported.

What we could not check

Every summary names the sources that could not be read this time. “We looked and found nothing” and “we could not look” are different facts, and you get told which one you have.

What does PROWL not do?
PROWL never makes up a market size of its own, and it does not rank markets by how attractive they are. Where a source states a size or a growth rate, we report it with the year, the region and who said it. A high score means a market is well supported by evidence — not that it is attractive. That judgement is made by a chemist with 30 years in the industry, working with you.
So a high score tells you where to look. It does not tell you what to do.